# Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

> **NCT00120796** · PHASE3 · TERMINATED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 8 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Lamivudine
- **BIOLOGICAL:** Recombinant hepatitis B surface antigen

## Key facts

- **NCT ID:** NCT00120796
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** poor patient recrutment
- **Last updated:** 2016-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00120796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00120796, "Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00120796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*